PD-L1 Biomolecules Associated with Clinical Features in Non-Melanoma Skin Cancer

Overview

Journal Clin Cosmet Investig Dermatol

Publisher Dove Medical Press

Specialty Dermatology

Date 2023 Jan 11

PMID 36628329

Authors

Dan Li

Liwen Ma

Jun Bao

Lei Cao

Wei Min

Affiliations

Soon will be listed here.

Abstract

Background: Increasing evidence has indicated that several B7 family members play critical roles in the progress of many cancers. However, the clinical significance of the B7 family in cutaneous squamous cell carcinoma (cSCC) is still elusive. The purpose of this study is to investigate the potential role of B7-H1 biomolecules (PD-L1) in regulating the tumorigenesis and progression of cSCC, the most common non-melanoma skin cancer.

Methods: We collected transcriptome data of cSCC patients from TCGA databases (n = 496) and subjected the transcription data to bioinformatical analysis. Differential expression of B7-H1 genes with a grade-dependent pattern was identified. We collected paraffin sections of skin squamous carcinoma and analyzed by immunohistochemical staining. We further examined the PD-L1 levels of CD14+ cells in peripheral blood of each cSCC patient and normal subjects by flow cytometry.

Results: It was found that higher expression of PD-L1 was associated with poor prognosis of cSCC patients and shorter overall survival. These observations were further verified in the clinical paraffin sections and in peripheral blood T cells.

Conclusion: Our study reveals that PD-L1 is a potential prognostic marker in clinical prognosis for cSCC patients and could be valuable for cSCC treatment.

Citing Articles

Aberrant expression of B7-H4 and B7-H5 contributes to the development of cutaneous squamous cell carcinoma.

Chen L, Zhou B, Tang M, Yao Y, Zhao Y, Hu Y Arch Dermatol Res. 2024; 316(7):382.

PMID: 38850312 PMC: 11162363. DOI: 10.1007/s00403-024-03095-w.

References

Yao Y, Tao R, Wang X, Wang Y, Mao Y, Zhou L . B7-H1 is correlated with malignancy-grade gliomas but is not expressed exclusively on tumor stem-like cells. Neuro Oncol. 2009; 11(6):757-66. PMC: 2802396. DOI: 10.1215/15228517-2009-014. View

Wang L, Ma Q, Li D, Mu S, Li Y, Wang Y . Indoleamine 2, 3-dioxygenase and B7-H1 expressions as prognostic and follow-up markers in human pancreatic carcinoma. Pathol Res Pract. 2018; 214(9):1309-1314. DOI: 10.1016/j.prp.2018.02.016. View

Taube J, Anders R, Young G, Xu H, Sharma R, McMiller T . Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med. 2012; 4(127):127ra37. PMC: 3568523. DOI: 10.1126/scitranslmed.3003689. View

Haanen J, Robert C . Immune Checkpoint Inhibitors. Prog Tumor Res. 2015; 42:55-66. DOI: 10.1159/000437178. View

Que S, Zwald F, Schmults C . Cutaneous squamous cell carcinoma: Incidence, risk factors, diagnosis, and staging. J Am Acad Dermatol. 2018; 78(2):237-247. DOI: 10.1016/j.jaad.2017.08.059. View

Zhao L, Li C, Zhang R, Xue H, Zhang F, Zhang F . B7-H1 and B7-H4 expression in colorectal carcinoma: correlation with tumor FOXP3(+) regulatory T-cell infiltration. Acta Histochem. 2014; 116(7):1163-8. DOI: 10.1016/j.acthis.2014.06.003. View

Geng Y, Wang H, Lu C, Li Q, Xu B, Jiang J . Expression of costimulatory molecules B7-H1, B7-H4 and Foxp3+ Tregs in gastric cancer and its clinical significance. Int J Clin Oncol. 2014; 20(2):273-81. DOI: 10.1007/s10147-014-0701-7. View

Tao J, Dai J, Hou S . Association between B7-H1 and cervical cancer: B7-H1 impairs the immune response in human cervical cancer cells. Exp Ther Med. 2017; 14(5):4125-4133. PMC: 5658695. DOI: 10.3892/etm.2017.5100. View

Karasar P, Esendagli G . T helper responses are maintained by basal-like breast cancer cells and confer to immune modulation via upregulation of PD-1 ligands. Breast Cancer Res Treat. 2014; 145(3):605-14. DOI: 10.1007/s10549-014-2984-9. View

10.

Kakavand H, Rawson R, Pupo G, Yang J, Menzies A, Carlino M . PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK Inhibitors. Clin Cancer Res. 2017; 23(20):6054-6061. DOI: 10.1158/1078-0432.CCR-16-1688. View

11.

Safaei H, Rostamzadeh A, Rahmani O, Mohammadi M, Ghaderi O, Yahaghi H . Prognostic investigations of B7-H1 and B7-H4 expression levels as independent predictor markers of renal cell carcinoma. Tumour Biol. 2015; 37(6):7583-7. DOI: 10.1007/s13277-015-4652-z. View

12.

Soura E, Gagari E, Stratigos A . Advanced cutaneous squamous cell carcinoma: how is it defined and what new therapeutic approaches are available?. Curr Opin Oncol. 2019; 31(5):461-468. DOI: 10.1097/CCO.0000000000000566. View

13.

Dong H, Zhu G, Tamada K, Chen L . B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med. 1999; 5(12):1365-9. DOI: 10.1038/70932. View

14.

Benson Jr D, Bakan C, Mishra A, Hofmeister C, Efebera Y, Becknell B . The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood. 2010; 116(13):2286-94. PMC: 3490105. DOI: 10.1182/blood-2010-02-271874. View

15.

Latchman Y, Wood C, Chernova T, Chaudhary D, Borde M, Chernova I . PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol. 2001; 2(3):261-8. DOI: 10.1038/85330. View

16.

Cheng R, Chen Y, Zhou H, Wang B, Du Q, Chen Y . B7-H3 expression and its correlation with clinicopathologic features, angiogenesis, and prognosis in intrahepatic cholangiocarcinoma. APMIS. 2018; 126(5):396-402. DOI: 10.1111/apm.12837. View

17.

Migden M, Rischin D, Schmults C, Guminski A, Hauschild A, Lewis K . PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. N Engl J Med. 2018; 379(4):341-351. DOI: 10.1056/NEJMoa1805131. View

18.

Kilic Bagir E, Acikalin A, Avci A, Gumurdulu D, Paydas S . PD-1 and PD-L1 expression in thymic epithelial tumours and non-neoplastic thymus. J Clin Pathol. 2018; 71(7):637-641. DOI: 10.1136/jclinpath-2017-204788. View

19.

Gadiot J, Hooijkaas A, Kaiser A, van Tinteren H, van Boven H, Blank C . Overall survival and PD-L1 expression in metastasized malignant melanoma. Cancer. 2011; 117(10):2192-201. DOI: 10.1002/cncr.25747. View

20.

Watanabe N, Gavrieli M, Sedy J, Yang J, Fallarino F, Loftin S . BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat Immunol. 2003; 4(7):670-9. DOI: 10.1038/ni944. View